Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WESTLAKE VILLAGE, CALIF., SEPT. 04, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THE GRANT OF AN AGGREGATE OF 57,000 RESTRICTED STOCK UNITS (RSUS) OF ARCUTIS COMMON STOCK TO 11 NEWLY HIRED EMPLOYEES. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF ARCUTIS' BOARD OF DIRECTORS AND GRANTED UNDER THE ARCUTIS BIOTHERAPEUTICS, INC. 2022 INDUCEMENT PLAN, WITH A GRANT DATE OF SEPTEMBER 1, 2026, AS A MATERIAL INDUCEMENT TO THE NEW EMPLOYEES IN CONNECTION WITH THEIR COMMENCEMENT OF EMPLOYMENT WITH ARCUTIS, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

WESTLAKE VILLAGE, CALIF., SEPT. 02, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC.(NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT ARCUTIS MANAGEMENT WILL PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE, TAKING PLACE SEPTEMBER 14-16, 2026, IN NEW YORK.

ARCUTIS MANAGEMENT TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

WESTLAKE VILLAGE, CALIF., AUG. 07, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THE GRANT OF AN AGGREGATE OF 143,500 RESTRICTED STOCK UNITS (RSUS) OF ARCUTIS' COMMON STOCK AS WELL AS OPTIONS TO PURCHASE AN AGGREGATE OF 37,000 SHARES OF ARCUTIS' COMMON STOCK TO 24 NEWLY HIRED EMPLOYEES.

CONTINUED STRONG ZORYVE (ROFLUMILAST) NET PRODUCT REVENUE GROWTH, WITH Q2 REVENUES OF $129.9 MILLION, +59% VERSUS Q2 OF 2025, AND +23% VERSUS Q1 OF 2026, DRIVEN PRIMARILY BY STRONG DEMAND GROWTH COMPANY RAISING 2026 FULL-YEAR NET PRODUCT SALES GUIDANCE TO $525 MILLION$540 MILLION RECEIVED APPROVAL TO EXPAND THE INDICATION FOR ZORYVE CREAM 0.3% FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS TO CHILDREN DOWN TO THE AGE OF 2, THE SEVENTH FDA APPROVAL IN FOUR YEARS FDA ACCEPTED SNDA FOR ZORYVE CREAM 0.05% TO EXPAND INDICATION TO INCLUDE INFANTS WITH MILD TO MODERATE ATOPIC DERMATITIS AGED 3 TO 24 MONTHS AND SET TARGET ACTION DATE OF FEBRUARY 23, 2027 COMPLETED ENROLLMENT OF THE PHASE 2 TRIAL OF ZORYVE FOAM 0.3% IN INDIVIDUALS WITH VITILIGO WITH DISCLOSURE OF TOPLINE RESULTS AND DECISION ON PROGRAM ADVANCEMENT ANTICIPATED IN Q4 OF 2026 LAUNCHED A VIRTUAL HEALTH PLATFORM AND A PARTNERSHIP WITH A LEADING AI-ENABLED HEALTHCARE PLATFORM TO HELP FACILITATE ACCESS TO ZORYVE MAINTAINED POSITIVE OPERATING CASH FLOW FOR THE QUARTER WESTLAKE VILLAGE, CALIF., AUG. 05, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026, AND PROVIDED A BUSINESS UPDATE.

ARCUTIS ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

WESTLAKE VILLAGE, CALIF., JULY 16, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATION IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT CHRISTOPHER CHRIS PEETZ HAS BEEN APPOINTED TO THE ARCUTIS BOARD OF DIRECTORS EFFECTIVE JULY 15, 2026.

ARCUTIS EXPANDS BOARD OF DIRECTORS WITH APPOINTMENT OF CHRIS PEETZ

WESTLAKE VILLAGE, CALIF., JULY 15, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT IT WILL REPORT ITS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE AFTER THE U.S. FINANCIAL MARKETS CLOSE ON WEDNESDAY, AUGUST 5, 2026.

Arcutis Biotherapeutics, Inc.

ARQT

Price

Financial Reports

No items found.

Press Releases

Arcutis Biotherapeutics, Inc.

ARQT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ARQT